[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-334374-105":59,"doc-detail-334374-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","incidence-and-risk-factors-for-venous-thromboembolism-in-gynecological-cancer-the-gotic-vte-trial","Incidence and risk factors for venous thromboembolism in gynecological cancer - the GOTIC-VTE trial","","Real-world evidence on venous thromboembolism (VTE) in Japanese patients with gynecological cancer is limited. The GOTIC-VTE trial evaluated VTE-associated event frequency and risk factors at cancer diagnosis and over 1-year follow-up. From July 2017 to February 2019, 1008 screened patients were enrolled; 881 were analyzed. Baseline VTE occurred in 5.8%, with most cases asymptomatic. Higher incidence was seen in ovarian, tubal, and peritoneal cancers. During follow-up, symptomatic VTE was 0.9% and composite VTE 3.5%. Chemotherapy independently increased composite VTE risk (HR 3.85).",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/incidence-and-risk-factors-for-venous-thromboembolism-in-gynecological-cancer-the-gotic-vte-trial/334374/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/incidence-and-risk-factors-for-venous-thromboembolism-in-gynecological-cancer-the-gotic-vte-trial/334374.png","ImageObject",300,407,{"name":92,"@type":93},"Valentina","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the main goal of the GOTIC-VTE trial?","Question",{"text":112,"@type":113},"To evaluate how often VTE-associated events occur and which risk factors are present at gynecological cancer diagnosis and during 1-year follow-up.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How many patients were analyzed, and what proportion had VTE at baseline?",{"text":117,"@type":113},"Of 1008 enrolled patients, 881 were included in the analysis set. At baseline, 51 patients (5.8%) had VTE, and most of these were asymptomatic.",{"name":119,"@type":110,"acceptedAnswer":120},"Which factor was identified as an independent risk factor for composite VTE during follow-up?",{"text":121,"@type":113},"Chemotherapy was an independent risk factor for composite VTE over the 1-year follow-up (hazard ratio 3.85, p=0.018).","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},334374,1790181980,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":4},13056703020460,"https://ap-avatar.wpscdn.com/avatar/be000253dac470eee5d?_k=1778207105932848923","Incidence and risk factors for venous thromboembolism in gynecological cancer: the GOTIC‑VTE trial  \nYoshifumi Takahashi1 · Hiroyuki Fujiwara1 · Kouji Yamamoto2 · Satoshi Yamaguchi3 · Shoji Nagao3,4 ·  \nMasashi Takano5 · Morikazu Miyamoto5 · Kosei Hasegawa6 · Maiko Miwa6 · Toshiaki Yasuoka7 · Soichi Yamashita8 · Takashi Hirakawa9 · Tomonori Nagai10 · Yoshinobu Hamada11 · Masaya Uno12 · Mayuyo Mori‑Uchino13 · Michitaka Ohwada14 · Akira Mitsuhashi15 · Toyomi Satoh16 · Keiichi Fujiwara6 · Mitsuaki Suzuki17 on behalf of the GOTIC‑VTE Trial Investigators  \nAccepted: 24 October 2024 / Published online: 27 November 2024 © The Author(s) 2024  \nAbstract  \nReal-world data on venous thromboembolism (VTE) in Japanese patients with gynecological cancer are lacking. The GOTICVTE trial aimed to evaluate the frequency of VTE-associated events and risk factors at the time of cancer diagnosis and during 1-year follow-up. From July 2017 to February 2019, patients with endometrial, cervical, ovarian, tubal, or peritoneal cancer who underwent VTE screening within 2 months before registration, were enrolled. Of the 1008 patients enrolled, 881 were included in the analysis set, 51 (5.8%) had VTE at the time of cancer diagnosis (baseline), 7 (0.8%) had symptomatic VTE, and the majority had asymptomatic VTE (n = 44; 5.0%). Patients with ovarian, tubal, or peritoneal cancer had a higher incidence of VTE (13.7%) than those with other cancer types. During the 1-year follow-up, 0.9%(n = 8) of the patients had symptomatic VTE, 3.5%(n = 31) had composite VTE (symptomatic VTE and incidental VTE requiring treatment), 0.2%(n = 2) had bleeding events, and 4.3%(n = 38) had all-cause death, all of which were significantly higher in the VTE group at baseline. In the multivariate analysis, chemotherapy was an independent risk factor for composite VTE during the 1-year follow-up (hazard ratio 3.85, 95% confidence interval 1.39–13.63, p = 0.018). Among gynecological cancers, VTE incidence  \n*  \n1  \n2  \n3  \n4  \n5  \n6  \n7  \n8  \nYoshifumi Takahashi [ytakahashi@jichi.ac.jp](ytakahashi@jichi.ac.jp)  \nDepartment of Obstetrics and Gynecology, School of Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi 329-0498, Japan  \nDepartment of Biostatistics, School of Medicine, Yokohama City University, Kanagawa, Japan  \nDepartment of Gynecologic Oncology, Hyogo Cancer Center, Hyogo, Japan  \nDepartment of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan  \nDepartment of Obstetrics and Gynecology, National Defense Medical College, Saitama, Japan  \nDepartment of Gynecologic Oncology, Saitama Medical University International Medical Center, Saitama, Japan  \nDepartment of Obstetrics and Gynecology, Ehime University, Graduate School of Medicine, Ehime, Japan  \nDepartment of Gynecology, Gunma Prefectural Cancer Center, Gunma, Japan  \n9 Department of Obstetrics and Gynecology, Gunma University Graduate School of Medicine, Gunma, Japan  \n10 Department of Obstetrics and Gynecology, Saitama Medical Center, Saitama Medical University, Saitama, Japan  \n11 Department of Obstetrics and Gynecology, Dokkyo Medical University Saitama Medical Center, Saitama, Japan  \n12 Department of Gynecology, National Cancer Center Hospital, Tokyo, Japan  \n13 Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan  \n14 Department of Obstetrics and Gynecology, International University of Health and Welfare, Tochigi, Japan  \n15 Department of Obstetrics and Gynecology, School of Medicine, Dokkyo Medical University, Tochigi, Japan  \n16 Department of Obstetrics and Gynecology, Institute of Medicine, University of Tsukuba, Ibaraki, Japan  \n17 Department of Obstetrics and Gynecology, Shinyurigaoka General Hospital, Kanagawa, Japan  \nis particularly high in ovarian, tubal, or peritoneal cancer, and patients undergoing chemotherapy should be cautioned a","cbCaijJ5wA8iY88y","https://ap.wps.com/l/cbCaijJ5wA8iY88y","pdf",1909663,"English","# Abstract\n## Trial design and enrollment\n## Baseline and follow-up outcomes\n## Risk factor analysis\n## Conclusions","[{\"question\":\"What was the main goal of the GOTIC-VTE trial?\",\"answer\":\"To evaluate how often VTE-associated events occur and which risk factors are present at gynecological cancer diagnosis and during 1-year follow-up.\"},{\"question\":\"How many patients were analyzed, and what proportion had VTE at baseline?\",\"answer\":\"Of 1008 enrolled patients, 881 were included in the analysis set. At baseline, 51 patients (5.8%) had VTE, and most of these were asymptomatic.\"},{\"question\":\"Which factor was identified as an independent risk factor for composite VTE during follow-up?\",\"answer\":\"Chemotherapy was an independent risk factor for composite VTE over the 1-year follow-up (hazard ratio 3.85, p=0.018).\"}]","Incidence and risk factors for venous thromboembolism in gynecological cancer - the GOTIC-VTE trial | PDF",1790006409,25]